Product Overview

Clofi 25 mg is a pharmaceutical formulation containing Clomiphene citrate, a selective estrogen receptor modulator widely recognized for its role in the treatment of female infertility. Manufactured by Sunrise Remedies Pvt Ltd, each strip contains ten tablets of 25 mg strength, and the product is available in pack sizes of 60, 120, or 180 tablets. The medication is indicated for women experiencing ovulatory dysfunction and is prescribed as part of a comprehensive fertility management plan. This overview provides medically accurate information, semantic SEO enhancements, and guidance on safe usage, enabling consumers and healthcare professionals to make informed decisions.

What is Clofi 25 mg (Clomiphene)

Clomiphene citrate functions by modulating estrogen receptors in the hypothalamus, leading to an increase in follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) secretion. This hormonal cascade promotes the development and release of mature ovarian follicles, thereby improving the chances of conception. The active ingredient belongs to the class of non‑steroidal fertility agents and is listed in authoritative sources such as the National Center for Biotechnology Information and the U.S. Food and Drug Administration. Clofi is not an anabolic steroid, nor does it contain any herbal extracts; its pharmacological profile is well documented in peer‑reviewed literature.

Uses and Benefits

The primary clinical use of Clofi 25 mg is the induction of ovulation in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders. When integrated with lifestyle modifications and assisted reproductive techniques, Clomiphene can increase pregnancy rates by up to 10‑15 percent per cycle in appropriately selected patients. Additional benefits include:

• Oral administration, which simplifies dosing compared with injectable gonadotropins.
• High selectivity for estrogen receptor modulation, minimizing off‑target effects.
• Proven track record supported by decades of clinical research, referenced by the MedlinePlus database.
• Compatibility with subsequent fertility interventions such as intrauterine insemination (IUI) or in‑vitro fertilization (IVF) when ovulation is successfully induced.

These attributes make Clofi a valuable option for couples seeking a cost‑effective, medically supervised pathway to pregnancy.

How It Works

Clomiphene citrate exerts its effect through partial agonism and antagonism at estrogen receptors in the central nervous system. By blocking estrogen feedback, the hypothalamus perceives low estrogen levels and responds by secreting increased amounts of gonadotropin‑releasing hormone (GnRH). This, in turn, stimulates the anterior pituitary to release FSH and LH, prompting the ovaries to develop multiple follicles. The resulting surge in LH triggers ovulation approximately 36‑48 hours after the final dose. The mechanism is well described in pharmacokinetic studies available through the National Institutes of Health.

Dosage Guidelines

Dosage should always be individualized by a qualified healthcare professional based on patient-specific factors such as age, ovarian reserve, and response to prior therapy. The typical recommended regimen involves one 25 mg tablet taken daily for five consecutive days, usually initiated on day 3 to day 5 of the menstrual cycle. Subsequent cycles may be repeated after a waiting period of at least one month. Adjustments may be made according to ovarian response, as monitored by ultrasound or hormone assays. Patients are advised to adhere strictly to the prescribed schedule and to avoid exceeding the recommended duration without medical supervision. For detailed dosing algorithms, refer to clinical guidelines published by the NIH.

Side Effects

Like all pharmacologic agents, Clofi may be associated with adverse effects. The most commonly reported side effects include hot flashes, abdominal discomfort, pelvic pressure, and breast tenderness. Less frequent but clinically significant events can involve visual disturbances, ovarian hyperstimulation syndrome (OHSS), and, rarely, thromboembolic phenomena. Patients should discontinue use and seek immediate medical attention if they experience severe abdominal pain, shortness of breath, or sudden vision changes. A comprehensive safety profile is maintained by regulatory bodies such as the FDA, which continues to monitor post‑marketing adverse event reports.

Warnings and Precautions

Prior to initiating therapy, a thorough medical evaluation should be performed to exclude pregnancy, liver dysfunction, or abnormal uterine bleeding of unknown etiology. Clofi is contraindicated in patients with known hypersensitivity to clomiphene or any component of the formulation. Caution is advised in women with a history of ovarian cysts, endometrial hyperplasia, or thromboembolic disorders. Concomitant use of other estrogen‑modulating agents should be avoided unless directed by a physician. Pregnant women must not use Clofi, as fetal exposure may lead to abnormal sexual development. For a complete list of contraindications and precautionary measures, consult the product’s prescribing information or reputable medical databases such as Drugs.com.

Frequently Asked Questions

Q1: How long does it take to see results after starting Clofi?
A: Ovulation typically occurs 6‑12 days after the final dose, and pregnancy may be achieved within the first few cycles if ovulation is successfully induced.

Q2: Can Clofi be used by women who have already conceived?
A: No. Clofi is indicated only for the induction of ovulation in women who have not yet achieved pregnancy; its use during confirmed pregnancy is unsafe.

Q3: Is Clofi suitable for men?
A: Clofi is specifically formulated for female infertility; its use in men is not supported by clinical evidence and should be avoided.

Q4: Are there dietary restrictions while taking Clofi?
A: No specific dietary limitations exist, but maintaining a balanced diet and healthy body weight can optimize ovulatory response.

Q5: What should I do if I miss a dose?
A: If a dose is missed, the patient should contact their healthcare provider for guidance; generally, the missed tablet should not be doubled.

For additional clinical resources and patient education materials, reputable sites such as the Mayo Clinic and the WebMD provide evidence‑based information on fertility treatments and medication safety.

Related Products

• DLX 30 mg (Duloxetine)
• DLX 60 mg (Duloxetine)
• DLX (Duloxetine)
• Grafix Capsules (Herbal)
• Grafix Cream 100 g (Herbal)
• Super Zudena (Udenafil/Dapoxetine)
• Extra Super P Force 100mg (Sildenafil/Dapoxetine)
• Extra Super Tadarise (Tadalafil/Dapoxetine)
• Femalegra 100 mg (Female Viagra)(Sildenafil Citrate)
• Malegra 50 mg (Sildenafil Citrate)
• Malegra Tablet
• Malegra 100 mg (Sildenafil Citrate)